Date published: 2025-12-24

1-800-457-3801

SCBT Portrait Logo
Seach Input

cyclin Y Inhibitors

Cyclin Y inhibitors belong to a class of chemical compounds designed to specifically target and modulate the activity of cyclin Y, a regulatory protein involved in cell cycle progression. Cyclin Y is a relatively newly discovered member of the cyclin family of proteins, which play critical roles in controlling cell division and proliferation. The inhibition of cyclin Y is primarily studied for its potential impact on cellular processes and its association with certain pathological conditions. These inhibitors are designed to interfere with the function of cyclin Y, thereby influencing the cell cycle and potentially offering insights into the fundamental mechanisms underlying cell division and growth regulation.

Cyclin Y inhibitors are typically small molecules that interact with specific binding sites on cyclin Y or its associated proteins. These interactions can disrupt the formation of active cyclin Y-CDK (Cyclin-Dependent Kinase) complexes, thereby preventing the activation of downstream signaling pathways involved in cell cycle control. By modulating cyclin Y activity, these inhibitors offer a valuable tool for researchers to dissect the intricate regulatory networks governing cell division. Moreover, understanding the molecular mechanisms through which cyclin Y inhibitors operate can shed light on the broader dynamics of cell cycle progression, making them a vital component of basic research aimed at elucidating the complexities of cellular biology and potentially identifying new avenues for further investigation into the role of cyclin Y in health and disease.

SEE ALSO...

Product NameCAS #Catalog #QUANTITYPriceCitationsRATING

RO-3306

872573-93-8sc-358700
sc-358700A
sc-358700B
1 mg
5 mg
25 mg
$65.00
$160.00
$320.00
37
(1)

Ro-3306 is a selective inhibitor of cyclin-dependent kinase 1 (CDK1) which regulates the G2/M cell cycle transition by inhibiting CDK1 activity, preventing cell cycle progression.

AZD 5438

602306-29-6sc-361115
sc-361115A
10 mg
50 mg
$205.00
$865.00
(0)

AZD5438 is a CDK inhibitor that targets CDK1, CDK2, and CDK9, blocking cell cycle progression and transcription in cancer cells.

Dinaciclib

779353-01-4sc-364483
sc-364483A
5 mg
25 mg
$242.00
$871.00
1
(0)

Dinaciclib inhibits CDK1, CDK2, CDK5, and CDK9, disrupting cell cycle progression and inhibiting transcription in cancer cells.

Flavopiridol

146426-40-6sc-202157
sc-202157A
5 mg
25 mg
$78.00
$254.00
41
(3)

Flavopiridol is a broad-spectrum CDK inhibitor that targets multiple CDKs, leading to cell cycle arrest and apoptosis in cancer cells.

SNS-032

345627-80-7sc-364621
sc-364621A
5 mg
10 mg
$169.00
$262.00
(1)

SNS-032 inhibits CDK2, CDK7, and CDK9, preventing cell cycle progression and transcription in cancer cells.

Palbociclib

571190-30-2sc-507366
50 mg
$315.00
(0)

Palbociclib specifically inhibits CDK4 and CDK6, halting cell cycle progression in hormone receptor-positive breast cancer.

R547

741713-40-6sc-364596
sc-364596A
2 mg
5 mg
$375.00
$395.00
(0)

R547 inhibits CDK1, CDK2, and CDK4, disrupting cell cycle regulation and inducing apoptosis in cancer cells.

Abemaciclib

1231929-97-7sc-507342
10 mg
$110.00
(0)

LY2835219 is a CDK4 and CDK6 inhibitor used to halt cell cycle progression in hormone receptor-positive breast cancer.

Zotiraciclib

937270-47-8sc-507450
10 mg
$202.00
(0)

This compound, also called TG-02, inhibits CDK2, CDK7, and CDK9, affecting cell cycle progression and transcription in cancer cells.

Ribociclib

1211441-98-3sc-507367
10 mg
$450.00
(0)

Ribociclib is a CDK4 and CDK6 inhibitor used to block cell cycle progression in hormone receptor-positive breast cancer.